

## MODERN GERIATRIC GIANTS: SARCOPENIA AND FRAILITY

Dr Joanne Kua, Dr Daphne Yang

### ABSTRACT

**A large proportion of older adults visit family physicians within the community. It is imperative for the family physician to be familiar with not just the common geriatric syndromes but also to be aware of modern geriatric giants such as sarcopenia and frailty as they are associated with adverse outcomes that can significantly affect an older adult's function. Simple screening tools like SARC-F and FRAIL scale can readily identify sarcopenia and frailty. Management is multi-pronged, focusing especially on resistance exercises and protein supplementation.**

**Keywords: Older adults, sarcopenia, frailty, management**

**SFP2024; 50(3): 30-34**

### INTRODUCTION

In 1965, Professor Bernard Issacs coined the original “Geriatric Giants” of immobility, instability, incontinence, and impaired memory. Since then, the science and the practice of Geriatrics have evolved and the “Modern Giants of Geriatrics” have become frailty,<sup>1</sup> sarcopenia,<sup>2</sup> anorexia of ageing,<sup>3</sup> and cognitive impairment.<sup>4</sup>

The importance of these giants lies in their association with common presentations for older adults such as falls, functional decline, depression, and delirium. In this article, we will discuss frailty and sarcopenia, and how practitioners in the primary health setting will be able to recognise them and manage them.

### SARCOPENIA

“Sarcopenia” is a term introduced by Rosenberg in 1988. It is derived from the Greek roots “*sarx*” for flesh and “*penia*” for loss<sup>5</sup> and refers to the age-related loss of muscle mass. Evidence suggests that after the age of 30 years, muscle mass declines at a rate of approximately 1 percent per year. This rate of muscle loss increases with age; in those above 80 years of age, the muscle mass decline is severe and ranges

from 11 to 50 percent.<sup>6-8</sup> Whether sarcopenia is a natural process of ageing or a condition that needs to be diagnosed and managed has been widely debated. Research over the last two decades has uncovered its association with many adverse health outcomes that are common in older adults, hence driving the current movement for early evaluation and intervention to halt the onset of these outcomes.

The scientific definition of sarcopenia has been challenging for clinicians because of the lack of clear cutoff values for the measurement of muscle mass as well as the quantification of strength. There have been many consensus groups aiming to give a clinical meaning to the word “sarcopenia”. The inconsistent research correlating muscle mass and strength<sup>9</sup> led to the incorporation of strength and physical performance in addition to muscle mass in the definition of sarcopenia.<sup>6,9-11</sup> The European Workgroup for Sarcopenia in Older Adults (EWGSOP) was instrumental in paving the way for sarcopenia diagnosis by proposing a clinical algorithm for evaluating sarcopenia, while the Asian Working Group for Sarcopenia (AWGS) provided diagnostic cutoff values for the Asian population, given the differences in body composition between Caucasians and Asians.<sup>12</sup> While local cutoffs are yet to be developed, a workgroup in Singapore has developed clinical practice guidelines to contextualise the current evidence in our own setting to facilitate the adoption of the above consensus statements into our clinical practice.<sup>13</sup>

Different consensus groups have proposed different operational definitions for sarcopenia as shown in **Table 1**. Essentially, sarcopenia is a condition that is defined by low muscle mass with low muscle strength resulting in low physical performance. As a guide, muscle mass is measured using either dual energy X-ray absorptiometry (DXA) or bioimpedance analysis (BIA). Muscle strength is measured by isometric handgrip strength using the dynamometer and physical performance requires either the short physical performance battery (SPPB) or gait speed.<sup>11</sup>

**Table 1: Different workgroups defining sarcopenia**

Group	Low muscle mass	Low muscle strength	Low physical performance
ESPEN (2010)	√		√
EWGSOP (2010)	√	√	√
International Working Group on Sarcopenia (2011)	√		

---

DR JOANNE KUA  
Senior Consultant and Consultant Geriatrician  
Tan Tock Seng Hospital

DR DAPHNE YANG  
Senior Consultant and Consultant Geriatrician  
Tan Tock Seng Hospital

Society of Sarcopenia, Cachexia and Wasting Disorders (2011)	√		√
Asian Working Group for Sarcopenia (2013)	√	√	√
Foundation for National Institutes of Health Sarcopenia Project (2014)	√	√	√

Most definitions of sarcopenia as detailed in **Table 1** are used in the context of research. It is difficult and impractical for community use due to the lack of accessibility to relevant measurement tools. The 5-item questionnaire SARC-F has been developed as a rapid diagnostic tool for sarcopenia in the community setting. It has excellent specificity but poor sensitivity and has been found to be comparable with three consensus definitions in predicting physical limitation and physical performance measures for four years.<sup>12</sup>

**Table 2: SARC-F screen for sarcopenia**

Component	Question	Scoring
Strength	How much difficulty do you have in lifting and carrying 10 pounds?	None = 0 Some = 1 A lot or unable = 2
Assistance in walking	How much difficulty do you have walking across a room?	None = 0 Some = 1 A lot, use aids, or unable = 2
Rise from a chair	How much difficulty do you have transferring from a chair or bed?	None = 0 Some = 1 A lot or unable without help = 2
Climb stairs	How much difficulty do you have climbing a flight of 10 stairs?	None = 0 Some = 1 A lot or unable = 2
Falls	How many times have you fallen in the last year?	None = 0 1-3 falls = 1 4 or more falls = 2
≥4 predicts sarcopenia		

**Prevalence**

The prevalence of sarcopenia varies depending on the geographic region and age group where the studies were conducted. Using different operational criteria also gives rise to different rates. In general, long-term care facilities have the highest proportion of sarcopenia, ranging from 14

to 33 percent. This proportion drops to 10 percent in the acute hospital setting. Within community-dwelling older adults, it ranges from 1 to 29 percent.<sup>14</sup>

**Aetiology**

Numerous factors can accelerate the process of sarcopenia. Physical inactivity from a sedentary lifestyle and bed rest, and negative protein balance from increased degradation and decreased synthesis, contribute to loss of muscle mass and power in older adults. **Figure 1** shows the rest of the factors contributing to sarcopenia.

**MANIFESTATIONS OF SARCOPENIA**

Sarcopenia can manifest as sarcopenic obesity, a clinical condition characterised not just by reduced muscle mass but also excess fat mass. In this condition, complications can arise both from sarcopenia and the cardiovascular risk burden from obesity. The other related condition is osteosarcopenia (the co-existence of sarcopenia with osteoporosis) due to the close interaction at the muscle-bone interface. Osteosarcopenia further worsens physical performance and the risk for falls, fractures, and disability compared to either osteoporosis or sarcopenia alone.<sup>15</sup>

**FRAILITY**


In **Figure 1**, we can see that sarcopenia is a precursor to frailty. Frailty is described as the inability of the body to respond to and withstand external stressors. It is characterised by increased vulnerability leading to negative health-related outcomes.<sup>16</sup> In older adults, physiological ageing affects the robustness of various homeostatic mechanisms. When faced with an acute insult, the inadequate physiological reserves result in functional decline. With further repetitive insults, the body reserves continue to weaken, leading to weaker homeostatic responses and further decline in function. The cumulative deficits result in disability and death when the body is unable to compensate.

Frailty is thus intricately linked to comorbidities and disability. This highlights its importance as it can aid in prognostication for patients with severe frailty and guide management towards being more conservative with earlier advance care planning discussions. On the other hand, patients at a pre-frail or mildly frail stage may potentially be able to revert to a more robust state if the acute insults are addressed early and reversed.

**Identifying Frailty**

The identification of frailty has been the subject of much debate and research. Currently, there exist more than 40 operational definitions of frailty.<sup>17</sup> There are three major models of classification: 1) The physical phenotype model, i.e., Fried’s frailty phenotype, FRAIL scale; 2) The deficit accumulation model, i.e., Frailty Index, Clinical Frailty Scale (CFS); and 3) Mixed physical and psychosocial models, i.e., Tilburg Frailty indicator, Edmonton Frailty Scale.

**Figure 1: Relationship between sarcopenia and its consequences**



The physical phenotype model remains the most popular model, and Fried’s frailty phenotype has been extensively researched upon. It is based on five predetermined criteria: involuntary weight loss; exhaustion; muscle weakness; slow gait speed; and sedentary behaviour.<sup>18</sup> The presence of three or more of these criteria will make the individual frail; prefrail if there are one or two criteria present; and robust if there are none.

The FRAIL scale<sup>19</sup> is a simple tool to evaluate frailty status for outpatients. **Table 3** shows the FRAIL instrument.

**Table 3: FRAIL instrument**

Symptom/Sign	Assessment
Fatigue	Are you fatigued?
Resistance	Can you walk up one flight of stairs?
Ambulation	Can you walk one block?
Illness	Do you have more than five illnesses?
Loss of weight	Have you lost more than 5 percent of your weight in the last six months?
≥3 = Frail; 1-2 = Prefrail; 0 = Robust	

The Clinical Frail Scale is another measurement of frailty that is gaining recognition. It uses clinical narratives and pictures to help stratify older adults according to their level of vulnerability. It is a strong predictor of institutionalisation and mortality and is comparable to the Fried’s frailty phenotype in identifying frailty status.<sup>20</sup>

**Prevalence of Frailty**

The prevalence of frailty is higher amongst those who are socioeconomically more disadvantaged. It ranges between 3.5-27 percent in community-dwelling older adults in Asia-Pacific, comparable to that in Europe and America.<sup>21</sup>

**Aetiology of Frailty**

Ageing, sarcopenia, polypharmacy, endocrine disorders, social isolation, and poverty can all lead to frailty.

**CLINICAL IMPLICATIONS OF SARCOPENIA AND FRAILTY**

The loss of muscle mass and strength in sarcopenia has been found to be correlated with adverse outcomes of physical disability, functional impairment,<sup>22,23</sup> falls,<sup>22,24,25</sup> increased dependency in activities of daily living,<sup>26</sup> increased risk of hospitalisation,<sup>27</sup> and increased mortality.<sup>28-30</sup> When frailty sets in, there will be increased risk of disability, hospitalisations, institutionalisation, and death.<sup>31</sup>

**PREVENTION AND TREATMENT OF SARCOPENIA AND FRAILTY**

Physical exercise, especially resistance exercise, has the most impact on sarcopenia and frailty. Many systematic reviews and meta-analyses have validated the importance of physical activity to maintain and improve physical strength, mobility, and function of older frail adults.<sup>32,33</sup> Progressive resistance training results in enhanced strength and is strongly recommended in the treatment of both sarcopenia and frailty.<sup>34</sup>

Nutrition is the building block for maintaining muscle mass and muscle capacity. It has been found that protein supplementation has been able to help treat sarcopenia.<sup>35,36</sup> Other studies have also found that a protein-enriched diet, amino acid plus leucine supplements, and b-hydroxy-b-methyl butyrate supplements all have a positive effect on muscle mass, strength, and performance.<sup>37</sup> It is recommended that older adults should have 25-30 g of high quality protein per meal to maximally stimulate skeletal muscle protein synthesis.<sup>38</sup>

The role of protein supplementation in treating frailty is more controversial as it has been found that improvement in nutritional status does not always translate into improved function or reduced mortality.<sup>39</sup> This highlights the need for a multimodal approach in managing frailty.

Other management strategies that could potentially target frailty are 1) reducing polypharmacy by reviewing and deprescribing inappropriate medications, and 2) vitamin D replacement in those who are deficient.<sup>40</sup>

## CONCLUSION

Sarcopenia and frailty are new geriatric giants that we need to be familiar with when we manage older adults. Like the old “giants”, they too result in consequences that can potentially be dire to older adults. It is pertinent for them to be identified and managed early in order to prevent adverse health outcomes.

## REFERENCES

- Morley JE, von Haehling S, Anker SD, Vellas B. From sarcopenia to frailty: a road less traveled. *J Cachexia Sarcopenia Muscle*. 2014 Mar;5(1):5-8. doi: 10.1007/s13539-014-0132-3. Epub 2014 Feb 14. PMID: 24526568; PMCID: PMC3953315.
- Argilés JM, Muscaritoli M. The Three Faces of Sarcopenia. *J Am Med Dir Assoc*. 2016 Jun 1;17(6):471-2. doi: 10.1016/j.jamda.2016.03.012. Epub 2016 May 5. PMID: 27161851.
- Morley JE. Pathophysiology of the anorexia of aging. *Curr Opin Clin Nutr Metab Care*. 2013 Jan;16(1):27-32. doi: 10.1097/MCO.0b013e328359efd7. PMID: 23041615.
- Morley JE, Morris JC, Berg-Weger M, et al. Brain health: The importance of recognizing cognitive impairment: an IAGG consensus conference. *J Am Med Dir Assoc*. 2015 Sep 1;16(9):731-9. doi: 10.1016/j.jamda.2015.06.017. PMID: 26315321; PMCID: PMC4822500.
- Rosenberg IH. Sarcopenia: origins and clinical relevance. *J Nutr*. 1997 May;127(5 Suppl):990S-991S. doi: 10.1093/jn/127.5.990S. PMID: 9164280.
- Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, aetiology, and consequences. International working group on sarcopenia. *J Am Med Dir Assoc*. 2011 May;12(4):249-56. doi: 10.1016/j.jamda.2011.01.003. Epub 2011 Mar 4. PMID: 21527165; PMCID: PMC3377163.
- von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. *J Cachexia Sarcopenia Muscle*. 2010 Dec;1(2):129-133. doi: 10.1007/s13539-010-0014-2. Epub 2010 Dec 17. PMID: 21475695; PMCID: PMC3060646.
- von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. *J Cachexia Sarcopenia Muscle*. 2010 Sep;1(1):1-5. doi: 10.1007/s13539-010-0002-6. Epub 2010 Oct 26. PMID: 21475699; PMCID: PMC3060651.
- Morley JE, Abbatecola AM, Argiles JM, et al. Sarcopenia with limited mobility: an international consensus. *J Am Med Dir Assoc*. 2011 Jul;12(6):403-9. doi: 10.1016/j.jamda.2011.04.014. PMID: 21640657; PMCID: PMC5100674.
- Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. *Clin Nutr*. 2010 Apr;29(2):154-9. doi: 10.1016/j.clnu.2009.12.004. Epub 2010 Jan 8. PMID: 20060626.
- Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*. 2019 Jul 1;48(4):601. doi: 10.1093/ageing/afz046. Erratum for: *Age Ageing*. 2019 Jan 1;48(1):16-31. PMID: 31081853; PMCID: PMC6593317.
- Woo J, Leung J. Anthropometric Cut Points for Definition of Sarcopenia Based on Incident Mobility and Physical Limitation in Older Chinese People. *J Gerontol A Biol Sci Med Sci*. 2016 Jul;71(7):935-40. doi: 10.1093/geron/glv197. Epub 2015 Oct 30. PMID: 26519945.
- Lim WS, Cheong CY, Lim JP, et al. Singapore Clinical Practice Guidelines For Sarcopenia: Screening, Diagnosis, Management and Prevention. *J Frailty Aging*. 2022;11(4):348-369. doi:10.14283/jfa.2022.59
- Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). *Age Ageing*. 2014 Nov;43(6):748-59. doi: 10.1093/ageing/afu115. Epub 2014 Sep 21. PMID: 25241753; PMCID: PMC4204661.
- Sepúlveda-Loyola W, Phu S, Bani Hassan E, et al. The Joint Occurrence of Osteoporosis and Sarcopenia (Osteosarcopenia): Definitions and Characteristics. *J Am Med Dir Assoc*. 2020;21(2):220-225. doi:10.1016/j.jamda.2019.09.005
- Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: a call to action. *J Am Med Dir Assoc*. 2013 Jun;14(6):392-7. doi: 10.1016/j.jamda.2013.03.022. PMID: 23764209; PMCID: PMC4084863.
- Theou O, Walston J, Rockwood K. Operationalizing Frailty Using the Frailty Phenotype and Deficit Accumulation Approaches. *Interdiscip Top Gerontol Geriatr*. 2015;41:66-73. doi: 10.1159/000381164. Epub 2015 Jul 17. PMID: 26301980; PMCID: PMC4886227.
- Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. *Cochrane Database Syst Rev*. 2009 Jul 8;(3):CD003945. doi: 10.1002/14651858.CD003945.pub3. Update in: *Cochrane Database Syst Rev*. 2018 Oct 05;10:CD003945. PMID: 19588348.
- Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. *J Nutr Health Aging*. 2012 Jul;16(7):601-8. doi: 10.1007/s12603-012-0084-2. PMID: 22836700; PMCID: PMC4515112.
- Islam A, Muir-Hunter S, Speechley M, Montero-Odasso M. Facilitating Frailty Identification: Comparison of Two Methods among Community-Dwelling Older Adults. *J Frailty Aging*. 2014;3(4):216-21. doi: 10.14283/jfa.2014.27. PMID: 27048860.
- Lee Y, Kim J, Han ES, Ryu M, Cho Y, Chae S. Frailty and body mass index as predictors of 3-year mortality in older adults living in the community. *Gerontology*. 2014;60(6):475-82. doi: 10.1159/000362330. Epub 2014 Jul 1. PMID: 24993678.
- Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc*. 2014 Feb;15(2):95-101. doi: 10.1016/j.jamda.2013.11.025. PMID: 24461239.
- Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. *J Am Geriatr Soc*. 2002 May;50(5):889-96. doi: 10.1046/j.1532-5415.2002.50216.x. PMID: 12028177.
- Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. *Am J Epidemiol*. 2004 Feb 15;159(4):413-21. doi: 10.1093/aje/kwh058. PMID: 14769646.
- Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women.

- Mech Ageing Dev. 1999 Mar 1;107(2):123-36. doi: 10.1016/s0047-6374(98)00130-4. PMID: 10220041.
26. Lord SR, Ward JA, Williams P, Anstey KJ. Physiological factors associated with falls in older community-dwelling women. *J Am Geriatr Soc.* 1994 Oct;42(10):1110-7. doi: 10.1111/j.1532-5415.1994.tb06218.x. PMID: 7930338.
  27. Rantanen T, Avlund K, Suominen H, Schroll M, Frändin K, Pertti E. Muscle strength as a predictor of onset of ADL dependence in people aged 75 years. *Aging Clin Exp Res.* 2002 Jun;14(3 Suppl):10-5. PMID: 12475129.
  28. Cawthon PM, Fox KM, Gandra SR, et al. Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? *J Am Geriatr Soc.* 2009 Aug;57(8):1411-9. doi: 10.1111/j.1532-5415.2009.02366.x. PMID: 19682143; PMCID: PMC3269169.
  29. Bigaard J, Frederiksen K, Tjønneland A, et al. Body fat and fat-free mass and all-cause mortality. *Obes Res.* 2004 Jul;12(7):1042-9. doi: 10.1038/oby.2004.131. PMID: 15292467.
  30. Cesari M, Pahor M, Lauretani F, et al. Skeletal muscle and mortality results from the InCHIANTI Study. *J Gerontol A Biol Sci Med Sci.* 2009 Mar;64(3):377-84. doi: 10.1093/gerona/gln031. Epub 2009 Jan 30. PMID: 19181709; PMCID: PMC2655006.
  31. Cesari M, Calvani R, Marzetti E. Frailty in Older Persons. *Clin Geriatr Med.* 2017 Aug;33(3):293-303. doi: 10.1016/j.cger.2017.02.002. Epub 2017 Apr 6. PMID: 28689563.
  32. Theou O, Stathokostas L, Roland KP, et al. The effectiveness of exercise interventions for the management of frailty: a systematic review. *J Aging Res.* 2011 Apr 4;2011:569194. doi: 10.4061/2011/569194. PMID: 21584244; PMCID: PMC3092602.
  33. Chou CH, Hwang CL, Wu YT. Effect of exercise on physical function, daily living activities, and quality of life in the frail older adults: a meta-analysis. *Arch Phys Med Rehabil.* 2012 Feb;93(2):237-44. doi: 10.1016/j.apmr.2011.08.042. PMID: 22289232.
  34. Oh SL, Kim HJ, Woo S, et al. Effects of an integrated health education and elastic band resistance training program on physical function and muscle strength in community-dwelling elderly women: Healthy Aging and Happy Aging II study. *Geriatr Gerontol Int.* 2017 May;17(5):825-833. doi: 10.1111/ggi.12795. Epub 2016 May 3. PMID: 27138245.
  35. Paddon-Jones D, Sheffield-Moore M, Katsanos CS, Zhang XJ, Wolfe RR. Differential stimulation of muscle protein synthesis in elderly humans following isocaloric ingestion of amino acids or whey protein. *Exp Gerontol.* 2006 Feb;41(2):215-9. doi: 10.1016/j.exger.2005.10.006. Epub 2005 Nov 23. PMID: 16310330.
  36. Dangin M, Guillet C, Garcia-Rodenas C, et al. The rate of protein digestion affects protein gain differently during aging in humans. *J Physiol.* 2003 Jun 1;549(Pt 2):635-44. doi: 10.1113/jphysiol.2002.036897. Epub 2003 Mar 28. PMID: 12665610; PMCID: PMC2342962.
  37. Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR. Aging is associated with diminished accretion of muscle proteins after the ingestion of a small bolus of essential amino acids. *Am J Clin Nutr.* 2005 Nov;82(5):1065-73. doi: 10.1093/ajcn/82.5.1065. PMID: 16280440.
  38. Paddon-Jones D, Rasmussen BB. Dietary protein recommendations and the prevention of sarcopenia. *Curr Opin Clin Nutr Metab Care.* 2009;12(1):86-90. doi:10.1097/MCO.0b013e32831cef8b
  39. Beck AM, Dent E, Baldwin C. Nutritional intervention as part of functional rehabilitation in older people with reduced functional ability: a systematic review and meta-analysis of randomised controlled studies. *J Hum Nutr Diet.* 2016 Dec;29(6):733-745. doi: 10.1111/jhn.12382. Epub 2016 May 27. PMID: 27231148.
  40. Dent E, Lien C, Lim WS, et al. The Asia-Pacific Clinical Practice Guidelines for the Management of Frailty. *J Am Med Dir Assoc.* 2017 Jul 1;18(7):564-575. doi: 10.1016/j.jamda.2017.04.018. Erratum in: *J Am Med Dir Assoc.* 2018 Jan;19(1):94. PMID: 28648901.

---

## LEARNING POINTS

- **Sarcopenia and frailty are modern geriatric giants and they need to be identified and managed as they can lead to serious consequences of falls, disability, institutionalisation, and death.**
  - **There is currently no consensus on the best screening tool to diagnose sarcopenia and frailty. It generally depends on the site and purpose of use.**
  - **Progressive resistance exercises and adequate protein intake can help in the management of sarcopenia and frailty.**
-